AstraZeneca Covid-19 vaccine put on hold after suspected adverse patient reaction
Wednesday, 09 September 2020
Original story here.
A large, Phase 3 study testing a Covid-19 vaccine being developed by AstraZeneca and the University of Oxford at dozens of sites across the U.S. has been put on hold due to a suspected serious adverse reaction in a participant in the United Kingdom.
A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
It was not immediately clear who placed the hold on the trial, though it is possible it was placed voluntarily by AstraZeneca and not ordered by any regulatory agency. The nature of the adverse reaction and when it happened were also not immediately known, though the participant is expected to recover, according to an individual familiar with the matter.
ENDS - more here
That news comes one day after this announcement from Greg Hunt.
Today is the day when Australia secured 84.8 million COVID-19 vaccine doses.
— Greg Hunt (@GregHuntMP) September 7, 2020
This will save lives and protect lives against the coronavirus.
WATCH: pic.twitter.com/csqt7J3G9G